Brief: Catalent To Acquire Cell Therapy Co Masthercell Global For $315 Mln
03/02/2020 12:59
Feb 3 (Reuters) - Catalent Inc CTLT.N :
* CATALENT TO ACQUIRE LEADING CELL THERAPY COMPANY
MASTHERCELL
GLOBAL FOR $315 MILLION, CREATING AN INDUSTRY-LEADING CELL &
GENE THERAPY PLATFORM
* CATALENT INC - ACQUISITION IS AN ALL-CASH TRANSACTION
* CATALENT INC - EXPECTS TO FINANCE WITH EITHER A PARTIAL
DRAWN
DOWN OF ITS REVOLVING CREDIT FACILITY OR PROCEEDS FROM FUTURE
CAPITAL-RAISING ACTIVITY
* CATALENT INC - AGREEMENT GOVERNING ACQUISITION IS NOT
CONTINGENT
ON ANY FINANCING ACTIVITY
* CATALENT INC - UPON COMPLETION OF DEAL, MASTHERCELL'S 240
EMPLOYEES, INCLUDING ITS LEADERSHIP TEAM, WILL BECOME PART OF
CATALENT BIOLOGICS BUSINESS
Source text for Eikon: ID:nBw6mGkLxa
Further company coverage: CTLT.N
(Reuters.Briefs@thomsonreuters.com)
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules